Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off
Executive Summary
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.
You may also be interested in...
Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn
Bristol-Myers Squibb has joined the big pharma trend of divesting non-core assets to focus on high-margin prescription drugs by agreeing to sell over-the-counter drugs business UPSA for $1.6bn to Japanese healthcare firm Taisho Pharmaceutical.
Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’
Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.
Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’
Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.